Medicinova Inc (MNOV) Stock Price, Quote & News

Company Profile

MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company develops MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent in Phase 2b/3 clinical trial for treating neurological and other disorders, such as progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical my...

Industry: Biotechnology

Sector: Healthcare

Phone: 858 373 1500

Fax: 858 404 0048

Website: medicinova.com

Address:

4275 Executive Square, Suite 300, La Jolla, United States

StreetwiseReports Feb. 2 at 6:44 PM

Biopharmaceutical Co. Looking for Breakthrough in US$987.6M ALS Treatment Market https://ow.ly/hEbB50Y7M7h Biopharmaceutical firm MediciNova Inc. ($MNOV:NASDAQ) reports that by the end of January, it has activated 12 sites in the U.S. and enrolled 100 patients in its study assessing its ALS treatment. Discover what one analyst suggests investors should watch for from the company in the upcoming year.

0 · Reply

StreetwiseReports Feb. 2 at 6:05 PM

Biopharma Reaches 50% Enrollment in New ALS Drug Program https://ow.ly/5yoQ50Y7KJB MediciNova Inc. ($MNOV:NASDAQ) enrolls 100 patients in the SEANOBI Expanded Access Program for MN-166 (ibudilast), noted a D. Boral Capital report. Read on to learn the many potential catalysts ahead for this California-based firm.

0 · Reply

prismmarketview Jan. 30 at 2:35 PM

MediciNova (NASDAQ: $MNOV) has enrolled 100 ALS patients in its SEANOBI expanded‑access program for MN‑166 (ibudilast), marking a key milestone as it advances late‑stage development of the therapy. https://prismmarketview.com/medicinova-reaches-100-patient-milestone-in-expanded-access-program-for-als-treatment/

0 · Reply

DARKP00L Jan. 29 at 11:14 PM

$MNOV 18:03 on Jan. 29 2026 MediciNova Reveals That As Of The End Of January 2026, 12 Sites In The US Are Activated And 100 Patients Have Been Enrolled In The SEANOBI Study #tradeideas

0 · Reply

OfficialStocktwitsUser Jan. 28 at 7:06 PM

$MNOV RSI: 75.64, MACD: 0.1090 Vol: 0.19, MA20: 1.55, MA50: 1.49 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

peepthestamp Jan. 24 at 1:15 AM

$MNOV

0 · Reply

peepthestamp Jan. 23 at 11:36 PM

$MNOV

0 · Reply

Lionish Jan. 23 at 3:11 PM

$MNOV On the move. Multiple catalysts this year. Slowly but surely…

0 · Reply

bowlerhatsftw Jan. 23 at 3:10 PM

$MNOV low key drift into battleground

0 · Reply

thepalace2007 Jan. 20 at 4:51 PM

$MNOV buy now $10 incoming

0 · Reply

MediciNova Announces 100 Patients Enrolled in SEANOBI Study Expanded-Access-Program (EAP) Evaluating MN‑166 (ibudilast) in ALS patients

Jan 6, 2026, 9:00 AM EST - 4 weeks ago

2026 New Year's Greetings from the CEO

Dec 18, 2025, 6:00 AM EST - 6 weeks ago

MediciNova Announces Completion of Patient Enrollment Evaluating MN-166 (ibudilast) in the Prevention of Chemotherapy-induced Peripheral Neuropathy

Dec 8, 2025, 6:00 AM EST - 2 months ago

MediciNova Announces Update and Basic Characteristic Randomized Patients' of Phase 2/3 Clinical Trial of MN-166 (Ibudilast) in ALS (COMBAT-ALS Clinical Trial) Presented at the 36th International Symposium on ALS/MND

Nov 18, 2025, 6:00 AM EST - 2 months ago

MediciNova Appoints Dr. Christopher Breder, MD, PhD as Clinical and Regulatory Advisor

Nov 6, 2025, 6:00 PM EST - 3 months ago

MediciNova Wins Contract Research and Development Innovation Award at 2025 BioTech Breakthrough Awards

Oct 30, 2025, 7:00 PM EDT - 3 months ago

MediciNova Compounds Demonstrate Novel Therapeutic Approach for Atherosclerosis in Peer-Reviewed Publication

Oct 6, 2025, 8:00 AM EDT - 4 months ago

MediciNova to Present at the LD Micro Main Event XIX Investor Conference

Sep 8, 2025, 9:00 AM EDT - 5 months ago

MediciNova Provides Shareholder Update on Key Developments

Sep 3, 2025, 7:00 AM EDT - 5 months ago

MediciNova to Present at the H.C. Wainwright 27th Annual Global Investment Conference

Aug 26, 2025, 7:00 PM EDT - 5 months ago

MediciNova Achieves Enrollment in COMBAT-ALS Clinical Trial

Jul 31, 2025, 7:30 PM EDT - 6 months ago

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

Jul 24, 2025, 6:00 AM EDT - 6 months ago

MediciNova Provides Enrollment Update for Ongoing ALS and Hypertriglyceridemia Clinical Trials

Apr 14, 2025, 7:00 PM EDT - 10 months ago

MediciNova To Participate in D. Boral's Capital Global Conference on May 14, 2025

Apr 8, 2025, 7:00 PM EDT - 10 months ago

First Patient Enrolled in NIH-Funded Expanded Access Program (EAP) Trial to Evaluate MN-166 in Amyotrophic Lateral Sclerosis (ALS) Patients

Dec 5, 2024, 6:00 PM EST - 1 year ago

MediciNova Presents Study Update and Interim Analysis of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS (COMBAT-ALS Clinical Trial) at the 35th International Symposium on ALS/MND

Nov 14, 2024, 6:00 PM EST - 1 year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-001 for Triglyceride Synthesis in the Liver

Nov 11, 2024, 6:00 PM EST - 1 year ago

MediciNova Given Notice of Monetary Damages Due Under Patent Settlement of Sanofi-Novartis

Oct 23, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Update of Phase 2/3 Clinical Trial of MN-166 (ibudilast) in ALS patients (COMBAT-ALS) at the 2024 Annual NEALS Meeting (Northeast Amyotrophic Lateral Sclerosis Consortium)

Sep 30, 2024, 9:00 AM EDT - 1 year ago

MediciNova to Support NIH-Funded Expanded Access Clinical Trial to Evaluate MN166 (ibudilast) in Amyotrophic Lateral Sclerosis (ALS)

Sep 9, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial Accepted for Poster Presentation at the 35th International Symposium on ALS / MND

Sep 3, 2024, 7:00 PM EDT - 1 year ago

MediciNova Announces Acceptance of Abstract Regarding MN-166 (ibudilast) in COMBAT-ALS Clinical Trial for Presentation at the 2024 Annual NEALS (Northeast Amyotrophic Lateral Sclerosis Consortium) Meeting

Aug 29, 2024, 7:00 PM EDT - 1 year ago

MediciNova Receives Notice of Allowance from United States Patent and Trademark Office for New Patent Covering MN-166 (ibudilast) for the Post-COVID Condition

Jun 20, 2024, 6:00 AM EDT - 1 year ago

MediciNova Chief Business Officer David H. Crean, Ph.D.

Jun 5, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Various Solid Cancer

Jun 3, 2024, 6:00 AM EDT - 1 year ago

MediciNova Announces Data from Phase 1b/2a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Patients at the American Society of Clinical Oncology (ASCO) Annual Meeting 2024

May 28, 2024, 6:00 AM EDT - 1 year ago

MediciNova Announces Two Poster Presentations at the 92nd EAS Congress 2024, the Annual Meeting of the European Atherosclerosis Society Regarding the Use of MN-001 (Tipelukast) for Cardiometabolic Conditions

May 20, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Prevention of Metastasis of Eye Cancer

May 14, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Chlorine-Induced Acute Respiratory Distress Syndrome

May 7, 2024, 6:00 AM EDT - 1 year ago

MediciNova Receives Issue Notification for New Patent Covering Extended-Release Formulations of MN-166 (ibudilast)

Apr 2, 2024, 7:00 PM EDT - 2 years ago

MediciNova Announces Abstract Regarding Results of a Clinical Trial of MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the 2024 American Society of Clinical Oncology Annual Meeting (2024 ASCO)

Mar 26, 2024, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Japan

Mar 20, 2024, 7:00 PM EDT - 2 years ago

MediciNova Announces Two Abstracts regarding MN-001 (tipelukast) and MN-002 Accepted for Presentation at the 92nd EAS 2024 Congress, the Annual Meeting of the European Atherosclerosis Society

Mar 12, 2024, 6:30 AM EDT - 2 years ago

MediciNova Announces New Data and Results of MN-166 (ibudilast) in Chlorine Gas-induced Acute Lung Injury Presented at the 63rd Annual Meeting of the Society of Toxicology

Jan 17, 2024, 6:00 AM EST - 2 years ago

MediciNova Receives a Notice of Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in China

Dec 21, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Chlorine Gas-induced Lung Injury Accepted for Presentation at the 63rd Annual Meeting of the Society of Toxicology

Dec 6, 2023, 6:00 PM EST - 2 years ago

MediciNova Receives a Notice of Decision to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Progressive MS in Europe

Nov 19, 2023, 6:00 PM EST - 2 years ago

MediciNova Announces New Data and Results of a Phase 2 Clinical Trial of MN-166 (ibudilast) in Glioblastoma Presented at the 28th Annual Meeting of the Society for Neuro-Oncology

Oct 27, 2023, 1:00 AM EDT - 2 years ago

MediciNova's Collaborator Initiates Clinical Development of a Gene Therapy Product for the Treatment of Phenylketonuria

Oct 10, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

Oct 4, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives Gene Therapy Milestone Payment

Sep 27, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Results of Studies under BARDA Contract to Develop MN 166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

Aug 17, 2023, 7:00 PM EDT - 2 years ago

MediciNova Announces Abstract Regarding MN-166 (ibudilast) in Glioblastoma Accepted for Presentation at the Annual Meeting of the Society for Neuro-Oncology

Aug 16, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for the Treatment of Macular Injury in Europe

Aug 15, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a New Patent Covering MN-001 for the Treatment of Scleroderma and Systemic Sclerosis in Europe

Aug 14, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-001 and MN-002 for the Treatment of Advanced NASH in Europe

Jun 29, 2023, 6:00 AM EDT - 2 years ago

MediciNova Announces Presentation of Results from the Phase 2b Trial of MN-166 (ibudilast) in Alcohol Use Disorder at the 46th Annual Research Society on Alcohol (RSA) Scientific Meeting

May 14, 2023, 7:00 PM EDT - 2 years ago

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering MN-166 (ibudilast) for Patients with Microorganism Infection in Europe

Apr 30, 2023, 7:00 PM EDT - 3 years ago

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 for the Treatment of Advanced NASH in Canada

Mar 9, 2023, 6:00 PM EST - 3 years ago

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

StreetwiseReports Feb. 2 at 6:44 PM

0 · Reply

StreetwiseReports Feb. 2 at 6:05 PM

0 · Reply

prismmarketview Jan. 30 at 2:35 PM

0 · Reply

DARKP00L Jan. 29 at 11:14 PM

$MNOV 18:03 on Jan. 29 2026 MediciNova Reveals That As Of The End Of January 2026, 12 Sites In The US Are Activated And 100 Patients Have Been Enrolled In The SEANOBI Study #tradeideas

0 · Reply

OfficialStocktwitsUser Jan. 28 at 7:06 PM

0 · Reply

peepthestamp Jan. 24 at 1:15 AM

$MNOV

0 · Reply

peepthestamp Jan. 23 at 11:36 PM

$MNOV

0 · Reply

Lionish Jan. 23 at 3:11 PM

$MNOV On the move. Multiple catalysts this year. Slowly but surely…

0 · Reply

bowlerhatsftw Jan. 23 at 3:10 PM

$MNOV low key drift into battleground

0 · Reply

thepalace2007 Jan. 20 at 4:51 PM

$MNOV buy now $10 incoming

0 · Reply

bowlerhatsftw Jan. 20 at 3:47 PM

$MNOV 1.72 drift resistance

1 · Reply

MuzunguZanz Jan. 15 at 8:41 PM

$MNOV This is a 8-10 months investment but if successful you guys should be at $10

1 · Reply

thepalace2007 Jan. 9 at 5:44 PM

$MNOV $5 incoming

1 · Reply

Penhouseview Jan. 8 at 3:10 AM

$MNOV

0 · Reply

OfficialStocktwitsUser Jan. 2 at 1:37 AM

$MNOV RSI: 20.59, MACD: -0.0432 Vol: 0.11, MA20: 1.44, MA50: 1.42 ⚪ HOLD - Sideways 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.

0 · Reply

StockElementCorporation Dec. 30 at 1:56 PM

Premarket movers 📈 Upside: $EKSO +44% (APLD to spin out cloud business; proposes combination with Ekso to launch Chronoscale) $ONTF +36% (to be acquired by Cvent for $8.10/share, ~$400M) $SCWO +13% (awarded PFAS waste destruction project for City of St. Cloud) $MNOV +5.5% (announces up to $50M equity distribution agreement) $TE +5.0% (executes $160M sale of Section 45X tax credits) DUOT +3.2% (announces additional Texas deployment and Illinois expansion) MOH +2.7% (constructive comments from Mike Burry) APLD +2.1% (cloud business spinout, Ekso combination proposal) Downside: IFRX -4.9% (Vilobelimab Phase 3 post-hoc analyses in pyoderma gangrenosum)

0 · Reply

SuperGreenToday Dec. 26 at 3:52 PM

$MNOV Share Price: $1.24 Contract Selected: Jul 17, 2026 $2.5 Calls Buy Zone: $0.04 – $0.05 Target Zone: $0.07 – $0.09 Potential Upside: 59% ROI Time to Expiration: 202 Days | Updates via https://fxcapta.com/stockinfo/

0 · Reply

LimeLightL Dec. 25 at 9:37 AM

$MNOV Expectations reset as evidence replaces narrative, given the heightened sensitivity to timeline slippage. Shortfalls would likely reprice expectations quickly.

1 · Reply

prismmarketview Dec. 18 at 4:11 PM

MediciNova (NASDAQ: $MNOV ) has completed enrollment in its investigator‑initiated Phase 2 OXTOX trial evaluating MN‑166 (ibudilast) to prevent chemotherapy‑induced peripheral neuropathy in metastatic colorectal cancer, with 100 patients randomized across 11 Australian sites and top‑line data expected in late 2026 after six‑month post‑chemo follow‑up. https://prismmarketview.com/medicinova-completes-enrollment-in-phase-2-study-of-mn-166-for-chemotherapy-induced-neuropathy/

0 · Reply

JarvisFlow Dec. 18 at 1:00 PM

D. Boral Capital has updated their rating for MediciNova ( $MNOV ) to Buy with a price target of 9.

0 · Reply

DARKP00L Dec. 18 at 11:13 AM

$MNOV 06:08 on Dec. 18 2025 MediciNova Completes Patient Enrollment in Mid-Stage Trial for Chemotherapy Nerve Damage #tradeideas

0 · Reply

Susiita81 Dec. 12 at 12:20 PM

$MNOV NEW!!! Ibudilast for Parkinson's disease https://onlinelibrary.wiley.com/doi/10.1111/jnc.70321

0 · Reply

Market Cap	84.53M
Revenue (ttm)	0.00
Net Income (ttm)	-11.04M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	66,100
Avg Vol	91,618
Day's Range	N/A - N/A
Shares Out	49.15M
Stochastic %K	25%
Beta	0.52
Analysts	Strong Sell
Price Target	$10.00